Cargando…

Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report

BACKGROUND: Bevacizumab is a monoclonal antibody drug targeting Vascular Endothelial Growth Factor (VEGF), which binds to VEGF receptors to inhibit vascular endothelial cell proliferation and angiogenesis, thus inhibiting tumorigenesis. Pembrolizumab is a monoclonal antibody that can bind to the pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yanxin, Dong, Changjiang, He, Xucheng, Wu, Pan, Shu, Yamin, Chen, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007831/ https://www.ncbi.nlm.nih.gov/pubmed/36899322 http://dx.doi.org/10.1186/s12882-023-03101-9

Ejemplares similares

A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
por: Shu, Yamin, et al.
Publicado: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
por: Shu, Yamin, et al.
Publicado: (2022)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
por: Shu, Yamin, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
por: Zhang, Qilin, et al.
Publicado: (2021)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
por: Franco, Thérèse H, et al.
Publicado: (2008)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
por: He, Ying, et al.
Publicado: (2022)

Metastatic testicular cancer presenting with hematuria and flank pain
por: González-Padilla, Daniel Antonio, et al.
Publicado: (2022)

Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report
por: Liu, Mei, et al.
Publicado: (2022)

Clinical values of urinary IL-6 in asymptomatic renal hematuria and renal hematuria with proteins
por: SONG, MINGHUI, et al.
Publicado: (2013)

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003
por: Dudek, Arkadiusz Z., et al.
Publicado: (2020)

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
por: Song, Haa-Na, et al.
Publicado: (2018)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Forgotten Kirschner Wire Causing Severe Hematuria
por: Kumar, Santosh, et al.
Publicado: (2014)

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
por: Yang, Gang, et al.
Publicado: (2022)

Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
por: Ercelep, Özlem, et al.
Publicado: (2020)

Long-Term 5-Year Response to Pembrolizumab, Bevacizumab, and Capecitabine Regimen in a Metastatic Colon Cancer Patient with MSI-High and KRAS Mutation: Case Report
por: Julka, Pramod Kumar, et al.
Publicado: (2023)

Familial hematuria
por: Kashtan, Clifford E.
Publicado: (2009)

Malarial Hematuria
por: Kilpatrick, J. J.
Publicado: (1895)

Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review
por: Skelton, William Paul, et al.
Publicado: (2018)

β2‐adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma
por: Schuster, Cornelia, et al.
Publicado: (2023)

Hematuria Is Associated with More Severe Acute Tubulointerstitial Nephritis
por: Esteras, Raquel, et al.
Publicado: (2020)

Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
por: Plummer, Chris, et al.
Publicado: (2019)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
por: Truong, Phu, et al.
Publicado: (2016)

Metastatic Porocarcinoma Effectively Managed by Pembrolizumab
por: Singh, Arminder, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Idiopathic renal arteriovenous fistula, a rare cause of severe hematuria: Case report
por: Valdez Vargas, Angel David, et al.
Publicado: (2018)

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
por: Acero Brand, Fanny Zulay, et al.
Publicado: (2018)

Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
por: Song, Lei, et al.
Publicado: (2020)

A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
por: Hakami, Osamah A, et al.
Publicado: (2019)

Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report
por: Thomas, Quentin Dominique, et al.
Publicado: (2022)

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
por: Yoshimoto, Toshiaki, et al.
Publicado: (2020)

Metastatic Bladder Cancer Presenting with Persistent Hematuria in Young Man with Cystic Fibrosis
por: Patel, Premal, et al.
Publicado: (2013)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report
por: Agarwal, Vijay, et al.
Publicado: (2008)

Mucocele of the appendix with hematuria.
por: Ng, K. C., et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_gp1ngqh078lta9062bqaqh9en9